Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
    • Education
  • Online Sections
    • COVID-19
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • Topics A-Z
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
    • Education
  • Online Sections
    • COVID-19
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • Topics A-Z
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

Share

April 06, 2015; 84 (14 Supplement) April 23, 2015

A Phase IIa Double-Blind, Placebo-Controlled Study to Evaluate the Safety of Oral Fingolimod In Patients with Amyotrophic Lateral Sclerosis (ALS) (P7.067)

James Berry, Sabrina Paganoni, Nazem Atassi, Namita Goyal, Michael Rivner, Ericka Simpson, Stanley Appel, Daniela Grasso, Nicte Mejia, Farrah Mateen, Merit Cudkowicz, Steven Perrin
First published April 8, 2015,
James Berry
9Neurological Clinical Research Institute Boston MA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sabrina Paganoni
1Boston MA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nazem Atassi
5Massachusetts General Hospital Boston MA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Namita Goyal
3Orange CA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Rivner
4Georgia Regents University Augusta GA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ericka Simpson
6Methodist Hospital Houston TX United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stanley Appel
7Methodist Neurological Institute Houston TX United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniela Grasso
8Neurological Clinical Research Institute MGH Boston MA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nicte Mejia
5Massachusetts General Hospital Boston MA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Farrah Mateen
5Massachusetts General Hospital Boston MA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Merit Cudkowicz
5Massachusetts General Hospital Boston MA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Steven Perrin
2Newbury MA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Citation
A Phase IIa Double-Blind, Placebo-Controlled Study to Evaluate the Safety of Oral Fingolimod In Patients with Amyotrophic Lateral Sclerosis (ALS) (P7.067)
James Berry, Sabrina Paganoni, Nazem Atassi, Namita Goyal, Michael Rivner, Ericka Simpson, Stanley Appel, Daniela Grasso, Nicte Mejia, Farrah Mateen, Merit Cudkowicz, Steven Perrin
Neurology Apr 2015, 84 (14 Supplement) P7.067;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
0

Share

  • Article
  • Info & Disclosures
Loading

Abstract

OBJECTIVE We conducted a Phase IIa randomized, placebo-controlled trial of fingolimod to investigate safety and tolerability and to explore biomarkers of immune change in people with ALS. BACKGROUND Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease affecting primarily the motor neurons and causing progressive weakness. An increasing body of research implicates immune activation in the progression of the disease. Fingolimod, an FDA-approved oral medication for the treatment of multiple sclerosis, is a functional antagonist of the sphingosine-1-phosphate (S1P) receptor, and sequesters lymphocytes in secondary lymph organs. SOD1G93A mouse experiments at ALSTDI suggested possible benefit in ALS. DESIGN/METHODS Thirty participants with ALS were randomized 2:1 fingolimod to placebo. Participants were monitored clinically for 8 hours at baseline. Treatment duration was 4 weeks with follow up visits at day 1 and weeks 2 and 4, and a follow-up phone call at 8 weeks. Lymphocyte counts were monitored by an independent reviewer. Blood was collected for safety monitoring and lymphocyte subset analysis at each visit, and RNA was collected at baseline and week 4. The primary outcome was tolerability, defined by the number of participants remaining on study drug, and safety as measured by occurrence of adverse events. Secondary outcome measures included analysis of circulating lymphocyte populations and gene expression analysis from blood. RESULTS The study enrolled from August 2013 to September 2014 and completed in October 2014. Two participants were withdrawn after randomization but prior to study drug initiation (one developed QTc prolongation, the other developed an infection). One participant was removed after initiating study drug for possible QT prolongation. No serious adverse events (SAEs) were reported. CONCLUSIONS The study met its primary endpoint for tolerability. Final clinical data monitoring and RNA analysis are underway. Full results will be presented at the 2015 AAN meeting. STUDY SUPPORTED BY ALS Therapy Development Institute

Disclosure: Dr. Berry has received personal compensation for activities with Oakstone Publishing as a speaker. Dr. Berry has received research support from the Muscular Dystrophy Association and ALS Therapy Alliance. Dr. Paganoni has nothing to disclose. Dr. Atassi has received personal compensation for activities with Biogen Idec as a consultant. Dr. Goyal has nothing to disclose. Dr. Rivner has received personal compensation for activities with Allergan, Inc. as a consultant. Dr. Rivner holds stock and/or stock options in Allergan Inc. Dr. Rivner has received research support from Allergan, Inc., and Cytokinetics. Dr. Simpson has received personal compensation for activities with Groefels as a speaker. Dr. Appel received personal compensation for activities with Neuraltus Pharmaceuticals, Inc. as a scientific advisory board member. Dr. Grasso has nothing to disclose. Dr. Mejia has nothing to disclose. Dr. Mateen has nothing to disclose. Dr. Cudkowicz has received personal compensation for activities with GlaxoSmithKline, Biogen Idec, Teva Neuroscience, and Cytokinetics. Dr. Cudkowicz has received personal compensation in an editorial capacity for JAMA Neurology. Dr. Perrin has received personal compensation for activities with Biogen Idec as an employee.

Thursday, April 23 2015, 2:00 pm-6:30 pm

  • Copyright © 2015 by AAN Enterprises, Inc.

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
  • Info & Disclosures
Advertisement

Related Articles

  • No related articles found.

Alert Me

  • Alert me when eletters are published

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • Neurology: Education
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2022 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise